- Home
- IMCR vs SPT Comparison
IMCR vs SPT Comparison
Compare IMCR & SPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCR | SPT |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 485.7M |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | IMCR | SPT |
|---|---|---|
| Price | $30.54 | $10.38 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 10 |
| Target Price | ★ $62.50 | $10.44 |
| AVG Volume (30 Days) | 291.3K | ★ 981.0K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 30.39 | ★ 32.11 |
| EPS | ★ 0.23 | N/A |
| Revenue | $249,428,000.00 | ★ $457,547,000.00 |
| Revenue This Year | $13.06 | $8.10 |
| Revenue Next Year | $8.12 | $6.01 |
| P/E Ratio | $136.00 | ★ N/A |
| Revenue Growth | ★ 43.05 | 12.72 |
| 52 Week Low | $27.56 | $4.92 |
| 52 Week High | $40.71 | $12.89 |
Technical Indicators
Market Signals| Indicator | IMCR | SPT |
|---|---|---|
| Relative Strength Index (RSI) | 31.60 | 49.91 |
| Support Level | $27.66 | $10.04 |
| Resistance Level | $31.56 | $10.56 |
| Average True Range (ATR) | 1.16 | 0.49 |
| MACD | -0.20 | -0.13 |
| Stochastic Oscillator | 10.79 | 44.42 |
Price Performance
Historical ComparisonAbout IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.